A Phase 2, single-arm, open-label study of gemtuzumab ozogamicin in adult patients with acute myeloid leukaemia in first relapse
Latest Information Update: 08 Sep 2017
Price :
$35 *
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms MyloFrance-1
- 08 Sep 2017 New trial record
- 01 Sep 2017 Results published in the Media Release
- 01 Sep 2017 According to a Pfizer media release, the US FDA approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML. The approval of MYLOTARG was based on several investigator-led clinical trials, including ALFA-0701, AML-19 and MyloFrance-1.